Lilly CEO Explains Drug Maker’s ‘Toughest Year’
In other drug industry news, the Centers for Medicare & Medicaid Services makes improvements in the new doctor payment website.
The Wall Street Journal: Lilly CEO Sees Light After A Difficult Year
Eli Lilly & Co. is deep into what Chief Executive John C. Lechleiter calls the “toughest year” in the drug maker’s 138-year history. Revenue at Lilly has plunged because of generic competition that followed patent expirations for several of its top-selling drugs, including the antidepressant Cymbalta (Loftus, 10/19).
The Wall Street Journal’s Pharmalot: Better Late Than Never: CMS Improves The Doctor Payment Website
Remember how challenging it was to navigate the new government database of payments made by drug and medical-device makers to U.S. doctors? Well, the transparency initiative just became a little easier to use – more than two weeks after the database was posted online (Loftus, 10/17).